Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity

Journal of Clinical Lipidology

Volumn 6, Issue 1, 2012, Pages 19-26

  Attridge, Rebecca L ^a,b,c   Linn, William D ^a,b   Ryan, Laurajo ^b,c   Koeller, Jim ^b,c   Frei, Christopher R ^b,c  

^a UNIVERSITY OF THE INCARNATE WORD   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Fenofibrate; Fenofibrate associated nephrotoxicity; Fibric aid derivatives; Nephrotoxicity

Indexed keywords

ACETAZOLAMIDE; AMLODIPINE; CREATININE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE; FELODIPINE; FENOFIBRATE; FUROSEMIDE; SPIRONOLACTONE; TRIAMTERENE; VERAPAMIL;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG USE; FEMALE; FENOFIBRATE ASSOCIATED NEPHROTOXICITY; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

ACUTE KIDNEY INJURY; AGED; BLOOD UREA NITROGEN; CREATININE; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOLIPIDEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84856219904     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.08.008     Document Type: Article

References (36)

1. N. Broeders, C. Knoop, M. Antoine, C. Tielemans, and D. Abramowicz Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 15 2000 1993 1999
2. C. Angeles, B.P. Lane, F. Miller, and E.P. Nord Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity Am J Kidney Dis 44 2004 543 550 (Pubitemid 39164630)
3. J. Lipscombe, G.F. Lewis, D. Cattran, and J.M. Bargman Deterioration in renal function associated with fibrate therapy Clin Nephrol 55 2001 39 44 (Pubitemid 32041781)
4. C.R. McQuade, J. Griego, J. Anderson, and A.B. Pai Elevated serum creatinine levels associated with fenofibrate therapy Am J Health Syst Pharm 65 2008 138 141
5. S.E. Nissen, S.J. Nicholls, and K. Wolski Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials JAMA 297 2007 1362 1373 (Pubitemid 46513237)
6. J.L. Ritter, and S. Nabulsi Fenofibrate-Induced elevation in serum creatinine Pharmacotherapy 21 2001 1145 1149 (Pubitemid 32807876)
7. J.C. Ansquer, R.N. Dalton, E. Causse, D. Crimet, K.L. Malicot, and C. Foucher Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people Am J Kidney Dis 51 2008 904 913 (Pubitemid 351697561)
8. C. Hottelart, N. El Esper, F. Rose, J.-M. Achard, and A. Fournier Fenofibrate increases creatininemia by increasing metabolic production of creatinine Nephron 92 2002 536 541
9. Antara package insert 2007 Oscient Pharmaceutical Emeryville
10. Tricor package insert 2007 Abbott Pharmaceutical Chicago
11. N. Pannu An overview of drug-induced acute kidney injury Crit Care Med 36 2008 S216-S23
12. M. Schetz, J. Dasta, S. Goldstein, and T. Golper Drug-induced acute kidney injury Curr Opin Crit Care 11 2005 555 565 (Pubitemid 41697327)
13. R.L. Mehta, J.A. Kellum, and S.V. Shah Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury Crit Care 11 2007 R31
14. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1 S266
15. A. Keech, R.J. Simes, P. Barter FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
16. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
17. G.M. Keating, and K.F. Croom Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus Drugs 67 2007 121 153 (Pubitemid 46105094)
18. N. Tarif, and G.L. Bakris Preservation of renal function: the spectrum of effects by calcium-channel blockers Nephrol Dial Transplant 12 1997 2244 2250 (Pubitemid 27474602)
19. G.R. Bailie, K. Uhlig, and A.S. Levey Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease Pharmacotherapy 25 2005 491 502 (Pubitemid 40471492)
20. L.A. Stevens, T. Greene, and A.S. Levey Surrogate end points for clinical trials of kidney disease progression Clin J Am Soc Nephrol 1 2006 874 884
21. K.C. Abbott, and G. Bakris Renal effects of antihypertensive medications: an overview J Clin Pharmacol 33 1993 392 399 (Pubitemid 23169231)
22. G.L. Bakris The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states J Am Soc Nephrol 2 1991 S21 S29
23. K.A. Griffin, M. Picken, G.L. Bakris, and A.K. Bidani Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model Hypertension 37 2001 1268 1272 (Pubitemid 34163580)
24. K. Hayashi, S. Wakino, N. Sugano, Y. Ozawa, and K. Homma Ca2+ channel subtypes and pharmacology in the kidney Circ Res 100 2007 342 353
25. N.R. Robles Calcium antagonists and renal failure progression Ren Fail 30 2008 247 255 (Pubitemid 351436368)
26. G.L. Bakris, K.A. Griffin, M.M. Picken, and A.K. Bidani Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury J Hypertens 15 1997 1181 1185 (Pubitemid 27420399)
27. C.N. Gashti, and G.L. Bakris The role of calcium antagonists in chronic kidney disease Curr Opin Nephrol Hypertens 13 2004 155 161 (Pubitemid 38373137)
28. P.A. Sarafidis, N. Khosla, and G.L. Bakris Antihypertensive therapy in the presence of proteinuria Am J Kidney Dis 49 2007 12 26 (Pubitemid 44918179)
29. S. Nathan, C.J. Pepine, and G.L. Bakris Calcium antagonists: effects on cardio-renal risk in hypertensive patients Hypertension 46 2005 637 642 (Pubitemid 43186729)
30. Y.J. Chen, and J. Quilley Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release J Pharmacol Exp Ther 324 2008 658 663 (Pubitemid 351185835)
31. M.W. Wilson, L.T. Lay, C.K. Chow, H.H. Tai, L.W. Robertson, and H.P. Glauert Altered hepatic eicosanoid concentrations in rats treated with the peroxisome proliferators ciprofibrate and perfluorodecanoic acid Arch Toxicol 69 1995 491 497
32. Z. Varghese, J.F. Moorhead, and X.Z. Ruan The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy Kidney Int 69 2006 1490-1391
33. X. Zhao, J.E. Quigley, J. Yuan, M.H. Wang, Y. Zhou, and J.D. Imig PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats Am J Physiol Heart Circ Physiol 290 2006 H2187 H2195
34. D.N. Muller, J. Theuer, and E. Shagdarsuren A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury Am J Pathol 164 2004 521 532 (Pubitemid 38364668)
35. M. Alonso-Galicia, B. Frohlich, and R.J. Roman Induction of P450 activity improves pressure-natriuresis in Dahl S rats Hypertension 31 1998 232 236
36. G.M. Felker, K.L. Lee, D.A. Bull, M.M. Redfield, and L.W. Stevenson Diuretic strategies in patients with acute decompensated heart failure N Engl J Med 364 2011 797 805